AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PRESCIENT THERAPEUTICS LTD

0.068

+0.0023.03%

Volume:300.66K

Turnover:20.20K

Market Cap:71.50M

PE:-10.00

High:0.068

Open:0.067

Low:0.066

Close:0.066

52wk High:0.125

52wk Low:0.041

Shares:1.05B

Float Shares:863.70M

Volume Ratio:0.35

T/O Rate:0.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.007

EPS(LYR):-0.007

ROE:-54.73%

ROA:-28.94%

PB:5.04

PE(LYR):-10.00

Loading ...

Overview Company News Filings

Prescient Therapeutics Ltd-Prescient Therapeutics - Extension of Share Purchase Plan

THOMSON REUTERS

Prescient Therapeutics Extends Share Purchase Plan Closing Date

MT Newswires Live

Prescient Therapeutics Ltd-Prescient Therapeutics - Extension of Share Purchase Plan

THOMSON REUTERS

Prescient Therapeutics Hits Dose Optimization Review Milestone in Cancer Drug Study

MT Newswires Live

Prescient Therapeutics Ltd-Share Purchase Plan Cleansing Notice

THOMSON REUTERS

Australia's Prescient Therapeutics Hits Near 2-Month Low on Discounted Raise

Prescient Therapeutics Launches Share Purchase Plan to Raise Up to AU$7 Million, Shares Fall 7%

MT Newswires Live

Prescient Therapeutics - Launches Spp to Raise A$7 Mln at A$0.065 Per Share

THOMSON REUTERS

Prescient Therapeutics Ltd-Prescient Therapeutics Launches Share Purchase Plan for $7M

THOMSON REUTERS

Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Simply Wall St.

Prescient Therapeutics Names Chief Medical Officer, Shares Jump 9%

MT Newswires Live

Prescient Therapeutics Ltd-Ptx DR Rosalind Wilson Appointed as Chief Medical Officer

THOMSON REUTERS

Prescient Therapeutics Ltd-March 2026 Quarterly Update and Appendix 4C

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/PTX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"PTX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PTX.AU\",,,,,undefined,":{"symbol":"PTX.AU","market":"AU","secType":"STK","nameCN":"PRESCIENT THERAPEUTICS LTD","latestPrice":0.068,"timestamp":1789529965268,"preClose":0.066,"halted":0,"volume":300655,"delay":0,"changeRate":0.030303030303030328,"nameEN":"PRESCIENT THERAPEUTICS LTD","floatShares":863697911,"shares":1051514543,"eps":-0.0068,"marketStatus":"Trading","change":0.002,"latestTime":"09-16 13:40:41 AEST","open":0.067,"high":0.068,"low":0.066,"amount":20201,"amplitude":0.030303,"askPrice":0.068,"askSize":173237,"bidPrice":0.067,"bidSize":20802,"shortable":3,"etf":0,"ttmEps":-0.0068,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789538400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.066,"openAndCloseTimeList":[[1789516800000,1789538400000]],"volumeRatio":0.345736,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PTX.AU","preClose":0.066,"auctionPrice":0.067,"auctionVolume":17000,"auctionTime":1789516740183,"referenceTime":1789468203091,"auction":1,"marketStatus":"盘前竞价","timestamp":1789516740183}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PTX.AU\",,,,,undefined,":{"symbol":"PTX.AU","floatShares":863697911,"roa":"-28.94%","roe":"-54.73%","lyrEps":-0.0068,"volumeRatio":0.345736,"shares":1051514543,"dividePrice":0,"high":0.068,"amplitude":0.030303,"preClose":0.066,"low":0.066,"week52Low":0.041,"pbRate":"5.04","psRate":"20.72","week52High":0.125,"institutionHeld":0,"latestPrice":0.068,"committee":-0.785589,"eps":-0.0068,"divideRate":0,"volume":300655,"delay":0,"ttmEps":-0.0068,"open":0.067,"prevYearClose":0.084,"prevWeekClose":0.068,"prevMonthClose":0.066,"prevQuarterClose":0.061,"fiveDayClose":0.065,"twentyDayClose":0.079,"sixtyDayClose":0.058,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667569924","title":"Prescient Therapeutics Ltd-Prescient Therapeutics - Extension of Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2667569924","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667569924?lang=en_us&edition=fundamental","pubTime":"2026-09-15 07:00","pubTimestamp":1789426817,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUEBBQWSP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTX.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665467673","title":"Prescient Therapeutics Extends Share Purchase Plan Closing Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2665467673","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665467673?lang=en_us&edition=fundamental","pubTime":"2026-09-08 10:06","pubTimestamp":1788833182,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  has extended the closing date of its share purchase plan  to Sept. 15 from Sept. 8, giving eligible shareholders more time to participate in the AU$7 million capital raising following delays in receiving documentation, according to a Tuesday filing with the Australian bourse.Eligible shareholders can apply under the SPP for up to AU$30,000 worth of new shares at AU$0.065 each, per the filing.The funds will be used to support the advancement of PTX-100 beyond the Dose Optimization Committee meeting, expected in December, and to guide the study's continuation and further development, the filing added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","PTX.AU","BK7508","LENZ","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665348989","title":"Prescient Therapeutics Ltd-Prescient Therapeutics - Extension of Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2665348989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665348989?lang=en_us&edition=fundamental","pubTime":"2026-09-08 07:03","pubTimestamp":1788822214,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nTUE8B6FQW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTX.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664999896","title":"Prescient Therapeutics Hits Dose Optimization Review Milestone in Cancer Drug Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2664999896","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664999896?lang=en_us&edition=fundamental","pubTime":"2026-09-02 13:38","pubTimestamp":1788327489,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  reached the pre-specified enrollment threshold for its first planned dose optimization committee review in a phase 2a study of its PTX-100 drug candidate in relapsed or refractory cutaneous T-cell lymphoma, according to a Wednesday filing with the Australian bourse.The company said 10 evaluable patients, or those who have completed four cycles of treatment, are now enrolled in each of the study's two dosing arms for 20 evaluable patients in total.The first dose optimization committee review remains on track for December, and enrollment in the study continues globally toward a full target of 40 evaluable patients.Cutaneous T-cell lymphoma is a type of immune system cancer where abnormal white blood cells migrate to and attack the skin.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4139","PTX.AU","BK7508","LENZ","BK4007","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662750700","title":"Prescient Therapeutics Ltd-Share Purchase Plan Cleansing Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2662750700","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662750700?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:46","pubTimestamp":1787697960,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUEWR71Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PTX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662478598","title":"Australia's Prescient Therapeutics Hits Near 2-Month Low on Discounted Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2662478598","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662478598?lang=en_us&edition=fundamental","pubTime":"2026-08-25 12:57","pubTimestamp":1787633876,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Prescient Therapeutics hits near 2-month low on discounted raise** Shares of Australia's Prescient TherapeuticsPTX.AXfall as much as 4.2%, their lowest level since July 2** Shares hit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL6N44M092:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTX.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662785801","title":"Prescient Therapeutics Launches Share Purchase Plan to Raise Up to AU$7 Million, Shares Fall 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662785801","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662785801?lang=en_us&edition=fundamental","pubTime":"2026-08-25 12:28","pubTimestamp":1787632124,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  launched a share purchase plan  to raise up to AU$7 million, with new fully paid ordinary shares to be issued at AU$0.065 per share, according to a Tuesday Australian bourse filing.The company said the issue price represents an 18.8% discount to the volume-weighted average price over the 10 trading days before the SPP was disclosed and a 9.7% discount to the last price.The company's shares fell 7% in recent Tuesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK4007","PTX.AU","BK4139","BK7508","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662620101","title":"Prescient Therapeutics - Launches Spp to Raise A$7 Mln at A$0.065 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2662620101","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662620101?lang=en_us&edition=fundamental","pubTime":"2026-08-25 07:06","pubTimestamp":1787612777,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUE3XTG7J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","PTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201019","title":"Prescient Therapeutics Ltd-Prescient Therapeutics Launches Share Purchase Plan for $7M","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201019","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201019?lang=en_us&edition=fundamental","pubTime":"2026-08-25 07:06","pubTimestamp":1787612777,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUE3XTG7J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","PTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649667019","title":"Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2649667019","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649667019?lang=en_us&edition=fundamental","pubTime":"2026-07-07 05:53","pubTimestamp":1783374809,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ptx/prescient-therapeutics-shares/news/heres-why-were-not-too-worried-about-prescient-therapeutics-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ptx/prescient-therapeutics-shares/news/heres-why-were-not-too-worried-about-prescient-therapeutics-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7067","PTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642084454","title":"Prescient Therapeutics Names Chief Medical Officer, Shares Jump 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642084454","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642084454?lang=en_us&edition=fundamental","pubTime":"2026-06-11 10:53","pubTimestamp":1781146424,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  appointed Rosalind Wilson as its Chief Medical Officer , effective Saturday, according to a Thursday Australian bourse filing.Its current CMO, Marissa Lim, has decided to move into semi-retirement.Wilson was previously Chief Executive of Factor Therapeutics.Its shares jumped 9% in recent trading on Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","PTX.AU","BK4539","BK4007","CMO.AU","BK7508","LENZ","BK4139","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642247405","title":"Prescient Therapeutics Ltd-Ptx DR Rosalind Wilson Appointed as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2642247405","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642247405?lang=en_us&edition=fundamental","pubTime":"2026-06-11 08:04","pubTimestamp":1781136241,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUEBBXCG0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","PTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631573689","title":"Prescient Therapeutics Ltd-March 2026 Quarterly Update and Appendix 4C","url":"https://stock-news.laohu8.com/highlight/detail?id=2631573689","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631573689?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:25","pubTimestamp":1777505110,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUEYQZHM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTX.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}]}}